(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Excelling at Discussion: Genuine Examples of overcoming adversity - 2Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- 3Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- 421 Things You Ought to Never Tell Your Childless Companion
- 5Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- A definitive Manual for Internet Mastering and Expertise Improvement
- Staggering Spots to Stargaze All over the Planet
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Motivational Travel Objections for History Buffs
- In these U.S. groups, deaths now exceed births. What’s happening?
